MétaCan
Menu
Back to cohort
Record W2534300912 · doi:10.1016/j.jalz.2016.06.808

P1‐061: Pharmacokinetics of Single and Multiple Rising Doses of BI 425809, A New Glyt1 Inhibitor, in Young and Elderly Healthy Volunteers

2016· article· en· W2534300912 on OpenAlexaff
Viktoria Moschetti, Christina Schlecker, Armin Schultz, Sven Wind, Sophia Goetz, Karl‐Heinz Liesenfeld, H. Schmitt, Yan Mao, Bailuo Ren, Glen Wunderlich, Sun-Young Angela Yum, Michael Desch

Bibliographic record

VenueAlzheimer s & Dementia · 2016
Typearticle
Languageen
FieldMedicine
TopicPharmacological Effects and Toxicity Studies
Canadian institutionsBoehringer Ingelheim (Canada)
Fundersnot available
KeywordsCmaxPharmacokineticsPlaceboTolerabilityBioavailabilityPharmacologyCrossover studyMedicineInternal medicineAdverse effect

Abstract

fetched live from OpenAlex

BI 425809, a glycine transporter-1 (GlyT1) inhibitor, is a new chemical entity being developed for the treatment of Alzheimer’s disease. These two trials examined safety, tolerability and characterised pharmacokinetics (PK) after single and multiple doses in young and elderly healthy volunteers (HV). Single rising-dose (SRD): placebo-controlled, single-blind using solution. Within-dose-group randomisation (3:1 drug:placebo) to nine groups (0.5/1/2/5/10/25/50/100/150mg). Bioavailability (BA): randomised, open-label, crossover. 25mg of solution/tablet under fasted/fed conditions. Multiple rising-dose (MRD): 12-day, double-blind, placebo-controlled. Within-dose group randomisation (3:1 drug:placebo) to seven groups (Young HV: 10/25/50/75mg qd; 75mg bid; elderly HV: 25/50mg). SRD: plasma PK profiles similar across dose groups, with rapid absorption and at least biphasic disposition phases. gMean plasma values for Cmax and AUC0-tz of 10.0-2970nmol/L and 115-46,600nmol∙h/L, from 0.5 to 150mg. Linear regression analysis of Cmax, and AUC0-tz provided a slope of ∼1 (dose proportional). Median tmax within 1h for all dose groups; gMean t1/2 from 32.5 to 47.0h. gMean fractional renal excretion consistent and low (∼5%) across all doses. BA: adjusted gMean ratios for Cmax and AUC0-tz for tablet vs solution of 50% (90% CI: 45%-55%), and 81% (74%-88%). Adjusted gMean ratios for Cmax and AUC0-tz∞ for tablet-fed vs tablet-fasted of 142% (128%-157%) and 126% (116%-137%). All AEs non-serious, and mild/moderate intensity, except one severe AE (vomiting) in the highest dose group, with trend towards dose dependency. MRD: tmax ∼4 hours, half-life ∼45 hours, steady state within 8 days. Accumulation ratios of 2.0-2.3× (Cmax) and 2.3-3.0× (AUC) with repeated dosing. Observed trend towards less-than- dose-proportional increase in exposure at doses ≥50 mg. Linearity index ∼1 for doses ≤75 mg qd, decreased at 75 mg bid. No detected PK or safety differences between young/elderly HV. All AEs non-serious and mild/moderate intensity, without dose dependency. BI 425809 PK are compatible with a once-daily dosing regimen, being dose-linear after single administration of 0.5 to 150 mg as solution. Exposure increased less-than-proportionally after administration of doses ≥50 mg as tablets; the compound has a low intrinsic dissolution rate. Exposure was similar in young and elderly HV. BI 425809 was generally well tolerated in all dose groups.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.001
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.309
Teacher spread0.272 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicPharmacological Effects and Toxicity StudiesFrench-language works237,207